475 related articles for article (PubMed ID: 32508311)
1. COVID-19 and androgen-targeted therapy for prostate cancer patients.
Bhowmick NA; Oft J; Dorff T; Pal S; Agarwal N; Figlin RA; Posadas EM; Freedland SJ; Gong J
Endocr Relat Cancer; 2020 Sep; 27(9):R281-R292. PubMed ID: 32508311
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor.
Mjaess G; Karam A; Aoun F; Albisinni S; Roumeguère T
Prog Urol; 2020 Sep; 30(10):484-487. PubMed ID: 32620366
[TBL] [Abstract][Full Text] [Related]
4. Targeting TMPRSS2 in SARS-CoV-2 Infection.
Baughn LB; Sharma N; Elhaik E; Sekulic A; Bryce AH; Fonseca R
Mayo Clin Proc; 2020 Sep; 95(9):1989-1999. PubMed ID: 32861340
[TBL] [Abstract][Full Text] [Related]
5. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of two potential novel SARS-CoV-2 entries, TMPRSS2 and IFITM3, in healthy individuals and cancer patients.
Dai YJ; Zhang WN; Wang WD; He SY; Liang CC; Wang DW
Int J Biol Sci; 2020; 16(15):3028-3036. PubMed ID: 33061814
[TBL] [Abstract][Full Text] [Related]
7. ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients.
Ravaioli S; Tebaldi M; Fonzi E; Angeli D; Mazza M; Nicolini F; Lucchesi A; Fanini F; Pirini F; Tumedei MM; Cerchione C; Viale P; Sambri V; Martinelli G; Bravaccini S
Cell Transplant; 2020; 29():963689720968749. PubMed ID: 33108902
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies.
Ragia G; Manolopoulos VG
Eur J Clin Pharmacol; 2020 Dec; 76(12):1623-1630. PubMed ID: 32696234
[TBL] [Abstract][Full Text] [Related]
10. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19.
Dong M; Zhang J; Ma X; Tan J; Chen L; Liu S; Xin Y; Zhuang L
Biomed Pharmacother; 2020 Nov; 131():110678. PubMed ID: 32861070
[TBL] [Abstract][Full Text] [Related]
11. Androgen-driven COVID-19 infection - is testosterone an enemy or a friend?
Grubić Kezele T
Horm Mol Biol Clin Investig; 2020 Jun; 41(2):. PubMed ID: 32598310
[No Abstract] [Full Text] [Related]
12. Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor
Nowak JK; Lindstrøm JC; Kalla R; Ricanek P; Halfvarson J; Satsangi J
Gastroenterology; 2020 Sep; 159(3):1151-1154.e2. PubMed ID: 32413354
[No Abstract] [Full Text] [Related]
13. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications.
Groß S; Jahn C; Cushman S; Bär C; Thum T
J Mol Cell Cardiol; 2020 Jul; 144():47-53. PubMed ID: 32360703
[TBL] [Abstract][Full Text] [Related]
14.
Bao R; Hernandez K; Huang L; Luke JJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32675312
[TBL] [Abstract][Full Text] [Related]
15. Do Anti-androgens Have Potential as Therapeutics for COVID-19?
Mauvais-Jarvis F
Endocrinology; 2021 Aug; 162(8):. PubMed ID: 34089595
[TBL] [Abstract][Full Text] [Related]
16. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094
[TBL] [Abstract][Full Text] [Related]
17. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis.
Hou Y; Zhao J; Martin W; Kallianpur A; Chung MK; Jehi L; Sharifi N; Erzurum S; Eng C; Cheng F
BMC Med; 2020 Jul; 18(1):216. PubMed ID: 32664879
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2: Potential Biomarker for COVID-19 Outcomes.
Strope JD; PharmD CHC; Figg WD
J Clin Pharmacol; 2020 Jul; 60(7):801-807. PubMed ID: 32437018
[No Abstract] [Full Text] [Related]
19. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
20. H
Yang G
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
